BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31584197)

  • 1. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
    Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
    Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
    Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
    Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal LAG-3
    Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral TIGIT
    Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
    BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
    Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
    Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of DC-SIGN
    Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor clinical outcomes and immunoevasive contexture in SIRPα
    Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
    Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
    Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
    Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
    BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral CCR5
    Xiang Z; Zhou Q; Zeng H; Wang Z; Zhang H; Liu Z; Huang Q; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Wang J; Guo J; Xu J
    Oncoimmunology; 2020 Aug; 9(1):1802176. PubMed ID: 32923162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
    Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
    Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.